Synta Pharmaceuticals: The Data Justify A Much Higher Share Price

11-08-2014 Seeking AlphaComments (0)

Synta PharmaceuticalsUSA

It has been some time since I have opined on Synta Pharmaceuticals (NASDAQ:SNTA). Since my last piece on Seeking Alpha covering this company, which was published on December 30, 2013, I have completed my PhD in epidemiology. As such, it felt it prudent to pick up writing about the biotech and healthcare sectors now that I have returned to Seeking Alpha. I previously made the call that Synta Pharmaceuticals was one of my top picks for 2014, specifically among biotechs working on cancer therapies. To my surprise, there has not been a single focus article on this stock since my last focus article. This is surprising, given that the average analyst price target is still over three times the current share price of the stock. That said, my opinion in December was based on the fact that the company may be sitting on a formulation which if effective, could

Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top